中国药物评价2016，Vol.33Issue(3)：150-152,3.
吉西他滨联合奈达铂治疗紫杉类耐药的三阴乳腺癌疗效观察
Gemcitabine Combined with Nedaplatin Therapy Taxane Resistant Term Efficacy of Triple-negative Breast Cancer
林秀欣 1周颖 1余更生 1方丽兰1
作者信息
- 1. 广东省江门市中心医院，广东江门529030
- 折叠
摘要
Abstract
Objective:To discuss the short-term effect of gemcitabine combined with nedaplatin in treatment of triple-negative breast cancer( TNBC) , explore the taxane resistant TNBC, and provide the basis for effective treatment options.Methods:74 patients with tax-ane resistant TNBC patients were randomly divided into 2 groups:experimental group and control group.Control group using conventional chemotherapy treatment.Experimental group gemcitabine combined with nedaplatin treatment.Gemcitabine in the first day and the eighth day intravenous infusion at a dose of 1000 mg/m2 , 30 min infusion finished.Nedaplatin, on the first day intravenous infusion at a dose of 80 mg/m2 .21 days for one cycle of chemotherapy, at least for two cycles of chemotherapy.Every two cycles to evaluate the efficacy of chemotherapy.During chemotherapy, the patient's condition were in the close observation of changes.Single-blind experimental methods, demographics and disease characteristics and comparative efficacy were used χ2 test.Results: The experimental group and the control group in terms of demographic and disease characteristics of the statistical test no significant difference (P>0.05).Experimental group, the number of valid cases 27 cases, the effective rate was 72.97%.Effective cases in the control group of 11 cases, the effective rate was 29.73%.The statistical test difference was statistically significant ( P<0.05 ) .Conclusion: Gemcitabine combined with nedaplatin therapy taxane resistant TNBC recent good effect, it may be a valid treatment options.关键词
吉西他滨/奈达铂/紫杉类耐药/三阴乳腺癌Key words
Gemcitabine/Nedaplatin/Taxane resistant/Triple-negative breast cancer(TNBC)分类
医药卫生引用本文复制引用
林秀欣,周颖,余更生,方丽兰..吉西他滨联合奈达铂治疗紫杉类耐药的三阴乳腺癌疗效观察[J].中国药物评价,2016,33(3):150-152,3.
